Comparison of Insulins (Canada)
(modified July 2024)
Click HERE to access the United States version of this resource.
This chart compares insulins in regard to duration, usual frequency, and cost. It also provides information on route of administration, stability of in-use products at room temperature, and place in therapy. See our toolbox, Improving Diabetes Outcomes, for more information on insulin and injectable diabetes meds.
--Information in this chart is from product monographs (see footnote a) unless otherwise specified.--
Insulin, Manufacturer |
Duration |
Usual Frequency |
Formulations/Costb |
Stability, in-use, room temp |
Rapid-acting: prandial human insulin analogues (rDNA origin). Onset 10 to 20 minutes (Fiasp faster.).1 For type 1 diabetes, recommended at each meal as part of an intensive basal-prandial regimen.1 For type 2 diabetes, as part of a “basal plus” strategyc or basal-bolus intensive regimend.1 All are given via subcutaneous injection. Humalog 100 unit/mL can be given intramuscularly but is not recommended. See chart below for those available for intravenous or subcutaneous infusions (pump). All are clear and colourless.1 |
||||
Humalog (insulin lispro), Eli Lilly (Liprelog, an “authorized biosimilar” made by Eli Lilly, has been approved, but not yet marketed; no cost available) |
3.5 to 4.75 hours |
One to three times daily.1 Inject within 15 min before a meal, or within 20 min after the start of the meal. |
100 units/mL: $34/10 mL vial $67/5 of 3 mL cartridges $67/5 of 3 mL KwikPen $71/5 of 3mL Junior KwikPen 200 units/mL: $125/5 of 3 mL KwikPen |
Vial, cartridge, pen: 28 days Pump reservoir (100 mL/mL): 14 days IV infusion:2 48 hours (0.1 to 1 unit/mL in NS) |
Admelog (insulin lispro), Sanofi-Aventis Biosimilar of Humaloge |
2 to 5 hours |
One to three times daily.1 Inject within 15 min before a meal, or within 20 min after the start of the meal. |
$25/10 mL vial $49/5 of 3 mL cartridges $49/5 of 3 mL SoloSTAR pens |
Vial, cartridge, pen: 28 days Pump reservoir: 14 days |
Kirsty (insulin aspart), BGP Pharma Biosimilar of NovoRapide |
3 to 5 hours |
One to three times daily.1 Inject 5 to 10 min before a meal, or immediately after the meal. |
$46/5 of 3 mL pre-filled pens | Vial, pen: 28 days |
Lyumjev (insulin lispro), Eli Lilly Approved, but not yet marketed |
3 to 5 hours | One to three times daily.1 Inject 0 to 2 min before a meal, or within 20 min after the start of the meal. |
100 units/mL: 10 mL vial 5 of 3 mL cartridges 5 of 3 mL KwikPen 5 of 3 mL Junior KwikPen 5 of 3 mL Tempo Pen 200 units/mL: 5 of 3 mL Kwik Pen Cost not available. |
Vial, cartridge, pen: 28 days IV infusion: 20 hours |
NovoRapid (insulin aspart), Novo Nordisk |
3 to 5 hours |
One to three times daily.1 Inject within 5 to 10 min before a meal, or immediately after the meal. |
$33/10 mL vial $67/5 of 3 mL Penfill cartridge $69/5 of 3 mL FlexTouch pens |
Vial, cartridge, pen: 28 days Pump reservoir: 6 days.3 IV infusion: 24 hours in D5W, D10W, or NS.2 |
Trurapi (insulin aspart), Sanofi-Aventis Biosimilar of NovoRapide |
3 to 5 hours |
One to three times daily.Inject within 5 to 10 min before a meal, or immediately after the meal. |
$49/5 of 3 mL cartridges $49/5 of 3 mL SoloSTAR pens |
Cartridge, pen: 28 days Pump reservoir: 6 days3 IV infusion: 24 hours (details in labeling) |
Apidra (insulin glulisine), Sanofi-Aventis |
4 hours |
One to three times daily.1 Inject within 15 min before a meal, or within 20 min after the start of the meal. |
$29/10 mL vial $57/5 of 3 mL cartridges $57/5 of 3 mL SoloStarpens |
Vial, cartridge, pen: 28 days Pump reservoir: 48 hours |
Fiasp (insulin aspart), Novo Nordisk Formulated with niacinamide for faster absorption. |
3 to 5 hours |
One to three times daily.1 Inject within 2 min before a meal, or within 20 min after the start of the meal. |
$32/10 mL vial $66/5 of 3 mL Penfill cartridge $68/5 of 3 mL FlexTouch pens |
Vial, cartridge, pen: 28 days Pump reservoir: 6 days IV infusion: 24 hours (0.5 to 1 unit/mL in NS or D5W) |
Short-acting (regular): regular human insulin of rDNA origin (Humulin R, Novolin ge Toronto, Entuzity), or pork insulin (Hypurin Regular). Onset about 15 minutes Entuzity, 30 minutes (Humulin R and Novolin ge Toronto), or up to 60 minutes for pork insulin. Longer time to onset and longer duration than rapid-acting analogues. For type 1 diabetes, recommended at each meal as part of an intensive basal-prandial regimen.1 For type 2 diabetes, as part of a “basal plus” strategyc or basal-bolus intensive regimend.1 Can be given via subcutaneous or intramuscular injection, or intravenous infusion. All are clear and colourless.1 |
||||
Humulin R 100 units/mL, Eli Lilly |
6 to 8 hours |
One to three times daily.1 Inject 30 to 45 min before meal.1 |
$28/10 mL vial $55/5 x 3 mL cartridges |
Vial, cartridge: 28 days IV infusion:2 48 hours (0.1 to 1 unit/mL in NS) |
Entuzity 500 units/mL, Eli Lilly |
17 to 24 hours |
Two to three times daily. Inject 30 minutes before meal. |
$106/2 of 3 mL KwikPen |
Pen: 28 days |
Myxredlin Baxter Biosimilar of Novolin ge Torontoe Approved but not yet marketed |
See Novolin ge Toronto |
0.3 to 1 unit/kg/day via IV infusion. (For emergencies[e.g., diabetic coma and pre-coma], patients with diabetes undergoing surgery.) |
IV infusion 1 unit/mL in |
IV infusion: 25 days |
Novolin ge Toronto, Novo Nordisk |
8 hours |
One to three times daily.1 Inject 30 minutes before meal. |
$26/10 mL vial $51/5 of 3 mL Penfill cartridges |
Vial, cartridge: 28 days IV infusion: 24 hours (details in labeling) |
Hypurin Regular, Wockhardt UK |
6 to 8 hours |
One to three times daily.1 Inject 30 to 45 min before meal.1 |
$107/10 mL vial |
Vial: 28 days |
Intermediate-acting (NPH): human insulin (rDNA origin) isophane suspension (Humulin N, Novolin ge NPH), or pork insulin isophane suspension (Hypurin NPH). For type 1 diabetes, may be used as the basal component of basal-prandial regimens.1 An initial insulin option in type 2 diabetes, often as a once-daily add-on to oral agents.1 As type-2 diabetes progresses, may be used as part of a “basal plus” strategyc or basal-bolus intensive regimend.1 Onset one to three hours.1 Administered via subcutaneous injection. Hypurin NPH can also be given IM (faster onset and shorter duration). All appear cloudy.1 |
||||
Novolin ge NPH, Novo Nordisk |
About 24 hours |
Once or twice daily. |
$26/10 ml vial $52/5 of 3 mL Penfill cartridges |
Vial, cartridge: 28 days |
Humulin N, Eli Lilly |
up to 24 hours |
Once or twice daily.1 |
$28/10 mL vial $55/5 of 3 mL cartridges $55/5 of 3 mL KwikPen |
Vial, cartridge, pen: 28 days |
Hypurin NPH, Wockhardt UK |
18 to 24 hours |
Once or twice daily.1 |
$107/10 mL vial |
Vial: 28 days |
Long-acting: human insulin analogue (rDNA origin). For type 1 diabetes, may be used as the basal component of basal-prandial regimens.1 An initial insulin option in type 2 diabetes, often as a once-daily add-on to oral agents.1 As type-2 diabetes progresses, may be used as part of a “basal plus” strategyc or basal-bolus intensive regimend.1 Administered via subcutaneous injection. All are clear and colourless.1 |
||||
Basaglar (insulin glargine), Eli Lilly Biosimilar of Lantuse |
See Lantus. |
Once daily at the same time each day. |
$78/ 5 of 3 mL cartridges $78/ 5 of 3 mLKwikPen |
Cartridge, pen: 28 days |
Lantus (insulin glargine), Sanofi-Aventis |
Median 24 hours (range 10.8 to >24 hours; sampling period 24 hours) |
Once daily at the same time each day. |
$67/10 mL vial $100/5 of 3 mL cartridges $100/5 of 3 mLSoloStar pens |
Vial, cartridge, pen: 28 days |
Levemir (insulin detemir), Novo Nordisk |
6 to 24 hours (dose-dependent; binds to albumin) |
Once daily, or twice daily as part of a basal-bolus regimen, with the evening dose administered with the evening meal or at bedtime. |
$117/5 of Penfill cartridges $120/5 of 3 mL FlexTouch pens |
Cartridge, pen: 42 days |
Semglee (insulin glargine) BGP Pharma Biosimilar to Lantuse |
See Lantus | Once daily at the same time each day. | $69/5 of 3 mL pens | Pen: 28 days |
Toujeo (insulin glargine), Sanofi-Aventis (300 units/mL) |
Up to 36 hours |
Once daily at the same time each day. First injection may provide insufficient coverage; may take at least 5 days to see maximum effect. |
$86/3 of 1.5 mL SoloStar pens $143/5 of 1.5 mL SoloStar pens $171/3 of 3 mL DoubleStar pen |
Pen: 42 days |
Ultra-Long-acting: human insulin analogue (rDNA origin). Administered via subcutaneous injection. May be beneficial for patients with adherence issues. All are clear and colourless.1
|
||||
Awiqli (insulin icodec) Novo Nordisk (700 units/mL) |
At least 1 week9 |
Once weekly |
$85 /1.5 mL FlexTouch pen $170 /3 mL FlexTouch pen |
Pen: 12 weeks |
Tresiba (insulin degludec), Novo Nordisk |
42 hours |
Once daily at the same time each day. |
100 units/mL: $120/5 of 3 mL FlexTouch pens 200 unit/mL: $144/5 of 3 mL FlexTouch pens |
Pen: 56 days |
Insulin Mixes: human insulin analogue (rDNA origin) solution and protamine-crystallized human insulin analogue suspension (NovoMix 30, Humalog Mix 25, Humalog Mix 50). Others are human insulin (rDNA origin) solution and human insulin isophane suspension. Generally, not appropriate for type 1 diabetes due to lack of dose flexibiltiy.1 Consider for elderly patients with type 2 diabetes due to ease of use.1 Typically added to oral agents.1 Given once or twice daily with breakfast and/or supper.1 Administered via subcutaneous injection. All appear cloudy.1 |
||||
NovoMix 30 (30% insulin aspart solution, 70% insulin aspart protamine suspension), Novo Nordisk |
Up to 24 hours |
Typically given pre-breakfast and/or pre-supper,1 immediately (not more than 5 to 10 min) before the meal, or immediately after the meal. |
$61/5 of 3 mL Penfill cartridges |
Cartridge: 28 days |
Humalog Mix 25 Eli Lilly |
Up to 22 hours |
Typically given pre-breakfast and/or pre-supper,1 within 15 min before the meal. |
$68/5 of 3 mL cartridges $68/5 of 3 mL KwikPen |
Cartridge, pen: 28 days |
Humalog Mix 50 (50% insulin lispro solution, 50% insulin lispro protamine suspension), Eli Lilly |
Up to 22 hours |
Typically given pre-breakfast and/or pre-supper,1 within 15 min before the meal. |
$67/5 of 3 mL cartridges $67/5 of 3 mL KwikPen |
Cartridge, pen: 28 days |
Humulin 30/70 (30% regular, 70% NPH), Eli Lilly |
Mean: 23 hours (range: 18 to |
Typically given pre-breakfast and/or pre-supper, about 30 to |
$28/10 mL vial $55/5 x 3 mL cartridges |
Vial, cartridge: 28 days |
Novolin ge 30/70 (30% regular, 70% NPH), Novo Nordisk |
About 24 hours |
Typically given pre-breakfast and/or pre-supper,1 within |
$26/10 mL vial $50/5 of 3 mL Penfill cartridges |
Vial, cartridge: 28 days |
Novolin ge 40/60 (40% regular, 60% NPH), Novo Nordisk |
About 24 hours |
Typically given pre-breakfast and/or pre-supper,1 within |
$50/5 of 3 mL Penfill cartridges |
Cartridge: 28 days |
Novolin ge 50/50 (50% regular, 50% NPH), Novo Nordisk |
About 24 hours |
Typically given pre-breakfast and/or pre-supper,1 within |
$50/5 of 3 mL Penfill cartridges |
Cartridge: 28 days |
- Product monographs used in creation of this chart: Humalog (April 2021), Kirsty (October 2021), Lyumjev (September 2021), NovoRapid (August 2021), Apidra (December 2021), Fiasp (July 2021), Trurapi (July 2022), Admelog (December 2021), Humulin (March 2021), Entuzity (March 2021), Myxredlin (August 2022), Novolin ge (August 2021), Hypurin Regular (June 2017), Hypurin NPH (June 2017), Basaglar (March 2021), Lantus (December 2021), Levemir (August 2021), Semglee (September 2022), Toujeo (October 2019), Awiqli (March 2024), Tresiba (July 2021), NovoMix 30 (August 2021).
- Wholesale acquisition cost (WAC).
- “Basal plus” strategy: rapid- or short-acting insulin once daily at main meal or breakfast plus basal insulin.1
- Basal-bolus intensive regimen: rapid- or short-acting insulin three times daily with meals plus basal insuilin.1
- Biosimilar products are not automatically interchangeable with the reference biologic drug. Each province/territory determines interchangeability.8
References
- Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2018 Apr;42 Suppl 1:S1-S325.
- Clinical Pharmacology powered by ClinicalKey. Tampa (FL): Elsevier. 2022. http://www.clinicalkey.com. (Accessed August 16, 2022).
- Senesh G, Bushi D, Neta A, Yodfat O. Compatibility of insulin Lispro, Aspart, and Glulisine with the Solo MicroPump, a novel miniature insulin pump. J Diabetes Sci Technol. 2010 Jan 1;4(1):104-10.
- Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017 Aug 24;377(8):723-732.
- Lane W, Bailey TS, Gerety G, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. JAMA. 2017 Jul 4;318(1):33-44.
- Wysham C, Bhargava A, Chaykin L, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA. 2017 Jul 4;318(1):45-56.
- Product information for Humulin 70/30. Eli Lilly and Company. Indianapolis, IN 46285. June 2022.
- Health Canada. Biosimilar biologic drugs in Canada: fact sheet. August 27, 2019. https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/fact-sheet-biosimilars.html. (Accessed August 15, 2022).
- Pieber TR, Asong M, Fluhr G, et al. Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 2 diabetes. Diabetes Obes Metab. 2023 Dec;25(12):3716-3723.
Cite this document as follows: Clinical Resource, Comparison of Insulins (Canada). Pharmacist’s Letter/Pharmacy Technician’s Letter. September 2022. [380917]